Breast cancer prevention: A review of current evidence

Ca-A Cancer Journal for Clinicians

Volumn 50, Issue 3, 2000, Pages 156-170

  Vogel, Victor G ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; DROLOXIFENE; ORAL CONTRACEPTIVE AGENT; RALOXIFENE; SEX HORMONE; TAMOXIFEN; TOREMIFENE;

ADULT; AGED; ALCOHOL CONSUMPTION; BODY WEIGHT; BREAST CANCER; CLINICAL TRIAL; COUNSELING; ENDOMETRIUM CANCER; EXERCISE; FEMALE; HEALTH PROMOTION; HUMAN; IONIZING RADIATION; LIFESTYLE; MASTECTOMY; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; REVIEW; RISK ASSESSMENT; SMOKING CESSATION; SUBSTITUTION THERAPY; VASCULAR DISEASE;

EID: 0034086613     PISSN: 00079235     EISSN: None     Source Type: Journal    
DOI: 10.3322/canjclin.50.3.156     Document Type: Review

References (94)

1. Greenlee RT, Murray T, Bolden S, Wingo PA: Cancer statistics, 2000. CA Cancer J Clin 2000;50:7-33.
2. Harris JR, Lippman ME, Veronesi U, Willett W: Breast cancer. N Engl J Med 1992;327:319-328.
3. Kelsey JL, Berkowitz GS: Breast cancer epidemiology. Cancer Res 1988;48:5615-5623.
4. Kelsey JL, Gammon MD: Epidemiology of breast cancer. Epidemiol Rev 1990;12:228-240.
5. Kelsey JL, Gammon MD, John EM: Reproductive factors and breast cancer. Epidemiol Rev 1993;15:36-47.
6. Spicer DV, Krecker EA, Pike MC: The endocrine prevention of breast cancer. Cancer Invest 1995;13:495-504.
7. Anderson TJ, Ferguson DJ, Raab GM: Cell turnover in the "resting" human breast: Influence of parity, contraceptive pill, age, and laterality. Br J Cancer 1982;46:376-382.
8. Daling JR, Malone KE, Voigt LF, et al: Risk of breast cancer among young women: Relationship to induced abortion. J Natl Cancer Inst 1994;86: 1584-1592.
9. Kelsey JL: A review of the epidemiology of human breast cancer. Epidemiol Rev 1979;1:74-109.
10. Gail MH, Brinton LA, Byar DP, et al: Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81: 1879-1886.
11. Bondy ML, Lustbader ED, Halabi S, et al: Validation of a breast cancer risk assessment model in women with a positive family history. J Natl Cancer Inst 1994;86:620-625.
12. Spiegelman D, Colditz GA, Hunter D, Hertzmark E: Validation of the Gail et al: model for predicting individual breast cancer risk. J Natl Cancer Inst 1994;86:600-607.
13. Gail MH, Benichou J: Epidemiology and biostatistics program of the National Cancer Institute. J Natl Cancer Inst 1994;86:573-575.
14. Costantino JP, Gail MH, Pee D, et al: Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 1999;91:1541-1548.
15. Carter CL, Allen C, Henson DE: Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989;63:181-187.
16. Honig SF: Hormonal therapy and chemotherapy, in Harris JR, Lippman ME, Morrow M, Hellman S (eds): Diseases of the Breast. Philadelphia, Lippincott-Raven Publishers, 1996, pp 669-734.
17. Love RR, Wiebe DA, Feyzi JM, et al: Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst 1994;86:1534-1539.
18. Love RR, Barden HS, Mazess RB, et al: Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Intern Med 1994;154:2585-2588.
19. Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-1388.
20. Stewart HJ: The Scottish trial of adjuvant tamoxifen in node-negative breast cancer. Scottish Cancer Trials Breast Group. J Natl Cancer Inst Monogr 1992;11:117-120.
21. Rutqvist LE, Johansson H, Signomklao T, et al: Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1995;87:645-651.
22. Baum M, Houghton J, Riley D: Results of the Cancer Research Campaign Adjuvant Trial for Perioperative Cyclophosphamide and Long-Term Tamoxifen in Early Breast Cancer reported at the tenth year of follow-up. Cancer Research Campaign Breast Cancer Trials Group. Acta Oncol 1992;21:251-257.
23. Fisher B, Costantino J, Redmond C, et al: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989;320:479-484.
24. Fisher B, Costantino JP, Redmond CK, et al: Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86:527-537.
25. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomized trials. Lancet 1998; 351:1451-1467.
26. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992;339:1-15.
27. Powles T, Eeles R, Ashley S, et al: Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998;352:98-101.
28. Veronesi U, Maisonneuve P, Costa A, et al: Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 1998;352: 93-97.
29. Gail MH, Costantino JP, Bryant J, et al: Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 1999;91:1829-1846.
30. Struewing JP, Hartge P, Wacholder S, et al: The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-1408.
31. Easton DF, Ford D, Bishop DT: Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995;56:265-271.
32. Thorlacius S, Struewing JP, Hartge P, et al: Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet 1998;352: 1337-1339.
33. Rajan JV, Marquis ST, Gardner HP, et al: Developmental expression of Brca2 colocalizes with Brcal and is associated with proliferation and differentiation in multiple tissues. Dev Biol 1997; 184:385-401.
34. Lane TF, Deng C, Elson A, et al: Expression of Brcal is associated with terminal differentiation of ectodermally and mesodermally derived tissues in mice. Genes Dev 1995;9:2712-2722.
35. Marks JR, Huper G, Vaughn JP, et al: BRCA1 expression is not directly responsive to estrogen. Oncogene 1997;14:115-121.
36. Marquis ST, Rajan JV, Wynshaw-Boris A, et al: The developmental pattern of Brcal expression implies a role in differentiation of the breast and other tissues. Nat Genet 1995;11:17-26.
37. Johannsson OT, Idvall I, Anderson C, et al: Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer 1997;33: 362-371.
38. Karp SE, Tonin PN, Begin LR, et al: Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer 1997;80:435-441.
39. Loman N, Johannsson O, Bendahl PO, et al: Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer 1998;83: 310-319.
40. Verhoog LC, Brekelmans CT, Seynaeve C, et al: Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 1998;351:316-321.
41. Wagner TM, Moslinger RA, Muhr D, et al: BRCA1-related breast cancer in Austrian breast and ovarian cancer families: Specific BRCA1 mutations and pathological characteristics. Int J Cancer 1998;77:354-360.
42. Cummings SR, Eckert S, Krueger KA, et al: The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281:2189-2197.
43. Spicer DV, Ursin G, Parisky YR, et al: Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer risk. J Natl Cancer Inst 1994;86:431-436.
44. Spicer DV, Pike MC, Pike A, et al: Pilot trial of a gonadotropin hormone agonist with replacement hormones as a prototype contraceptive to prevent breast cancer. Contraception 1993;47:427-444.
45. Lotan R: Retinoids in cancer chemoprevention. FASEB J 1996;10:1031-1039.
46. Lippman SM, Lee JJ, Sabichi AL: Cancer chemoprevention: Progress and promise. J Natl Cancer Inst 1998;90:1514-1528.
47. Hartmann LC, Schaid DJ, Woods JE, et al: Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999;340:77-84.
48. Eisen A, Weber BL: Prophylactic mastectomy -the price of fear. N Engl J Med 1999;340:137-138.
49. Howe GR, Hirohata T, Hislop TG, et al: Dietary factors and risk of breast cancer: Combined analysis of 12 case-control studies. J Natl Cancer Inst 1990;82:561-569.
50. Prentice RL, Kakar F, Hursting S, et al: Aspects of the rationale for the Women's Health Trial. J Natl Cancer Inst 1988;80:802-814.
51. Wynder EL, Fujita Y, Harris RE, et al: Comparative epidemiology of cancer between the United States and Japan. A second look. Cancer 1991;67:746-763.
52. Carroll KK, Khor HT: Dietary fat in relation to tumorigenesis. Prog Biochem Pharmacol 1975;10: 308-353.
53. Willett WC, Hunter DJ, Stampfer MJ, et al: Dietary fat and fiber in relation to risk of breast cancer. An 8-year follow-up. JAMA 1992;268: 2037-2044.
54. Hunter DJ, Willett WC: Diet, body size, and breast cancer. Epidemiol Rev 1993;15:110-132.
55. Hunter DJ, Spiegelman D, Adami HO, et al: Cohort studies of fat intake and the risk of breast cancer - a pooled analysis. N Engl J Med 1996; 334:356-361.
56. Holmes MD, Hunter DJ, Colditz GA, et al: Association of dietary intake of fat and fatty acids with risk of breast cancer. JAMA 1999;281:914-920.
57. Siiteri PK: Adipose tissue as a source of hormones. Am J Clin Nutr 1987;45:277-282.
58. Cauley JA, Gutai JP, Kuller LH, et al: The epidemiology of serum sex hormones in postmenopausal women. Am J Epidemiol 1989;129: 1120-1131.
59. Stoll BA: Teenage obesity in relation to breast cancer risk. Int J Obes Relat Metab Disord 1998;22:1035-1040.
60. Pujol P, Galtier-Dereure F, Bringer J: Obesity and breast cancer risk. Hum Reprod 1997;12(suppl 1):116-125.
61. Lash T, Aschengrau A: Active and passive cigarette smoking and the occurrence of breast cancer. Am J Epidemiol 1999;149:5-12.
62. Gammon M, Hiboosh H, Terry MB, et al: Oral contraceptive use and other risk factors in relation to HER-2/neu overexpression in breast cancer among young women. Cancer Epidemiol Biomarkers Prev 1999;8:413-419.
63. Muti P, Trevisan M, Micheli A, et al: Alcohol consumption and total estradiol in premenopausal women. Cancer Epidemiol Biomarkers Prev 1998;7:189-193.
64. Smith-Warner SA, Spiegelman D, Yaun SS, et al: Alcohol and breast cancer in women: A pooled analysis of cohort studies. JAMA 1998;279:535-540.
65. Ferraroni M, Decarli A, Franceschi S, La Vecchia C: Alcohol consumption and risk of breast cancer: A multicentre Italian case-control study. Eur J Cancer 1998;34:1403-1409.
66. Schatzkin A, Carter CL, Green SB, et al: Is alcohol consumption related to breast cancer? Results from the Framingham Heart Study. J Natl Cancer Inst 1989;81:31-35.
67. Longnecker MP: The Framingham results on alcohol and breast cancer. Am J Epidemiol 1999; 149:102-105.
68. Oliveria S, Christos P: The epidemiology of physical activity and cancer. Ann N Y Acad Sci 1997;833:79-90.
69. Hoffman-Goetz L, Apter D, Demark-Wahnefried W, et al: Possible mechanisms mediating an association between physical activity and breast cancer. Cancer 1998;83:621-628.
70. McTiernan A: Exercise and breast cancer - time to get moving? N Engl J Med 1997;336:1311-1312.
71. Frisch RE, Wyshak G, Albright NL, et al: Lower prevalence of breast cancer and cancers of the reproductive system among former college athletes compared to non-athletes. Br J Cancer 1985; 52:885-891.
72. Bernstein L, Henderson BE, Hanisch R, et al: Physical exercise and reduced risk of breast cancer in young women. J Natl Cancer Inst 1994;86:1403-1408.
73. D'Avanzo B, Nanni O, La Vecchia C, et al: Physical activity and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1996;5:155-160.
74. Friedenreich CM, Rohan TE: Physical activity and risk of breast cancer. Eur J Cancer Prev 1995;4:145-151.
75. Mittendorf R, Longnecker MP, Newcomb PA, et al: Strenuous physical activity in young adulthood and risk of breast cancer (United States). Cancer Causes Control 1995;6:347-353.
76. Vihko VJ, Apter DL, Pukkala EI, et al: Risk of breast cancer among female teachers of physical education and languages. Acta Oncol 1992;31:201-204.
77. Vena JE, Graham S, Zielezny M, et al: Occupational exercise and risk of cancer. Am J Clin Nutr 1987;45(suppl 1):318-327.
78. Zheng W, Shu XO, McLaughlin JK, et al: Occupational physical activity and the incidence of cancer of the breast, corpus uteri, and ovary in Shanghai. Cancer 1993;71:3620-3624.
79. Albanes D, Blair A, Taylor PR: Physical activity and risk of cancer in the NHANES I population. Am J Public Health 1989;79:744-750.
80. Thune I, Brenn T, Lund E, Gaard M: Physical activity and the risk of breast cancer. N Engl J Med 1997;336:1269-1275.
81. Taioli E, Barone J, Wynder EL: A case-control study on breast cancer and body mass. The American Health Foundation - Division of Epidemiology. Eur J Cancer 1995;31A:723-728.
82. Chen CL, White E, Malone KE, Daling JR: Leisure-time physical activity in relation to breast cancer among young women (Washington, United States). Cancer Causes Control 1997;8:77-84.
83. Paffenbarger RS Jr, Hyde RT, Wing AL: Physical activity and incidence of cancer in diverse populations: A preliminary report. Am J Clin Nutr 1987;45(suppl 1):312-317.
84. Dosemeci M, Hayes RB, Vetter R, et al: Occupational physical activity, socioeconomic status, and risks of 15 cancer sites in Turkey. Cancer Causes Control 1993;4:313-321.
85. Dorgan JF, Brown C, Barrett M, et al: Physical activity and risk of breast cancer in the Framingham Heart Study. Am J Epidemiol 1994;139:662-669.
86. Rockhill B, Willett WC, Hunter DJ, et al: A prospective study of recreational physical activity and breast cancer risk. Arch Intern Med 1999;159:2290-2296.
87. Collaborative Group on Hormonal Factors in Breast Cancer: Breast cancer and hormonal contraceptives: Collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996;347:1713-1727.
88. Colditz GA, Stampfer MJ, Willett WC, et al: Prospective study of estrogen replacement therapy and risk of breast cancer in postmenopausal women. JAMA 1990;264:2648-2653.
89. Colditz GA, Hankinson SE, Hunter DJ, et al: The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589-1593.
90. Brinton LA, Brogan DR, Coates RJ, et al: Breast cancer risk among women under 55 years of age by joint effects of usage of oral contraceptives and hormone replacement therapy. Menopause 1998;5:145-151.
91. Colditz GA: Hormone replacement therapy increases the risk of breast cancer. Ann N Y Acad Sci 1997;833:129-136.
92. Ron E: Ionizing radiation and cancer risk: Evidence from epidemiology. Radiat Res 1998;150: S30-S41.
93. Lundell M, Mattsson A, Karlsson P, et al: Breast cancer risk after radiotherapy in infancy: a pooled analysis of two Swedish cohorts of 17,202 infants. Radiat Res 1999;151:626-632.
94. Little MP, Boice JD Jr: Comparison of breast cancer incidence in the Massachusetts tuberculosis fluoroscopy cohort and in the Japanese atomic bomb survivors. Radiat Res 1999;151:218-224.